Updated on 2022/05/06

写真a

 
ANDO Yuichi
 
Organization
Nagoya University Hospital Clinical Oncology and Chemotherapy Professor
Graduate School
Graduate School of Medicine
Title
Professor
External link

Degree 1

  1. 医学博士 ( 1999.3   名古屋大学 ) 

Research Interests 1

  1. clinical oncology

Research Areas 1

  1. Others / Others  / 臨床腫瘍学

Research History 2

  1. Nagoya University   Nagoya University Hospital

    2018.8

  2. 名古屋大学医学部附属病院化学療法部教授

    2012.5

      More details

    Country:Japan

Education 2

  1. Nagoya University   Graduate School, Division of Medical Sciences

    1996.4 - 1999.3

      More details

    Country: Japan

  2. Nagoya University   Faculty of Medicine

    1984.4 - 1990.3

      More details

    Country: Japan

Professional Memberships 7

  1. 日本臨床腫瘍学会   理事

  2. 日本癌学会   評議員

  3. 日本臨床薬理学会   理事

  4. 日本がん治療学会

  5. American Society of Clinical Oncology

  6. 日本呼吸器学会

  7. 日本緩和医療学会

▼display all

Awards 1

  1. 日本癌学会奨励賞

    2004  

     More details

    Country:Japan

 

Papers 85

  1. Phase I study of alpelisib (BYL719), an alpha-specific PI3K inhibitor, in Japanese patients with advanced solid tumors

    Ando Yuichi, Iwasa Satoru, Takahashi Shunji, Saka Hideo, Kakizume Tomoyuki, Natsume Kazuto, Suenaga Naoko, Quadt Cornelia, Yamada Yasuhide

    CANCER SCIENCE   Vol. 110 ( 3 ) page: 1021 - 1031   2019.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1111/cas.13923

    Web of Science

    PubMed

  2. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial. Reviewed

    Hiroaki Tsukuura, Masayuki Miyazaki, Tatsuya Morita, Mihoko Sugishita, Hiroshi Kato, Yuka Murasaki, Bishal Gyawali, Yoko Kubo, Masahiko Ando, Masashi Kondo, Kiyofumi Yamada, Yoshinori Hasegawa and Yuichi Ando

    Oncologist   Vol. 23 ( 3 ) page: 367 - 374   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1634/theoncologist.2017-0225

    Web of Science

    PubMed

  3. Clinical effectiveness of geriatric assessment for predicting the tolerability of outpatient chemotherapy in older adults with cancer. Reviewed

    Naomi Hayashi, Ayumu Matsuoka, Hidemi Goto, Momokazu Gotoh, Hitoshi Kiyoi, Yasuhiro Kodera, Masato Nagino, Fumio Nagashima, Yuichi Ando.

    J Geriatr Oncol   Vol. 9 ( 1 ) page: 84 - 86   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/j.jgo.2017.07.014

    Web of Science

    PubMed

  4. Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan. Reviewed

    Sachi Morita, Toyone Kikumori, Nobuyuki Tsunoda, Takahiro Inaishi, Yayoi Adachi, Akiko Ota, Masahiro Shibata, Ayumu Matsuoka, Kenichi Nakanishi, Dai Takeuchi, Takehumi Mizutani, Tomoya Shimokata, Hiromichi Hayashi, Osamu Maeda and Yuichi Ando

    Int J Clin Oncol   Vol. 23 ( 1 ) page: 195 - 200   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s10147-017-1177-z

    Web of Science

    PubMed

  5. Association of drinking behaviors with TXNIP DNA methylation levels in leukocytes among the general Japanese population

    Maeda Keisuke, Yamada Hiroya, Munetsuna Eiji, Fujii Ryosuke, Yamazaki Mirai, Ando Yoshitaka, Mizuno Genki, Ishikawa Hiroaki, Ohashi Koji, Tsuboi Yoshiki, Hattori Yuji, Ishihara Yuya, Hashimoto Shuji, Hamajima Nobuyuki, Suzuki Koji

    AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE     2022.4

     More details

  6. Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline

    Iwama Shintaro, Kobayashi Tomoko, Yasuda Yoshinori, Okuji Takayuki, Ito Masaaki, Ando Masahiko, Zhou Xin, Yamagami Ayana, Onoue Takeshi, Kawaguchi Yohei, Miyata Takashi, Sugiyama Mariko, Takagi Hiroshi, Hagiwara Daisuke, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Wakahara Keiko, Yokota Kenji, Kato Masashi, Nishio Naoki, Tanaka Chie, Miyata Kazushi, Ogura Atsushi, Ito Takanori, Sawada Tsunaki, Shimokata Tomoya, Niimi Kaoru, Ohka Fumiharu, Ishigami Masatoshi, Gotoh Momokazu, Hashimoto Naozumi, Saito Ryuta, Kiyoi Hitoshi, Kajiyama Hiroaki, Ando Yuichi, Hibi Hideharu, Sone Michihiko, Akiyama Masashi, Kodera Yasuhiro, Arima Hiroshi

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM   Vol. 107 ( 4 ) page: E1620 - E1630   2022.3

     More details

  7. Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade

    Miyai Yuki, Sugiyama Daisuke, Hase Tetsunari, Asai Naoya, Taki Tetsuro, Nishida Kazuki, Fukui Takayuki, Chen-Yoshikawa Toyofumi Fengshi, Kobayashi Hiroki, Mii Shinji, Shiraki Yukihiro, Hasegawa Yoshinori, Nishikawa Hiroyoshi, Ando Yuichi, Takahashi Masahide, Enomoto Atsushi

    LIFE SCIENCE ALLIANCE   Vol. 5 ( 6 )   2022.3

     More details

  8. A phase I study of LCL161, a novel oral pan-inhibitor of apoptosis protein (IAP) antagonist, in Japanese patients with advanced solid tumors

    Morita Sachi, Minami Hironobu, Mitsuma Ayako, Toyoda Masanori, Kiyota Naomi, Ando Yuichi

    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY     2022.1

     More details

  9. Preoperative docetaxel, cisplatin, and fluorouracil treatment with pegfilgrastim on day 7 for patients with esophageal cancer: A phase II study

    Maeda Osamu, Fukaya Masahide, Koike Masahiko, Miyata Kazushi, Kanda Mitsuro, Nishida Kazuki, Ando Masahiko, Kodera Yasuhiro, Ando Yuichi

    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY     2022.1

     More details

  10. [Chemotherapy for Older Patients with Cancer].

    Mitsuma A, Ando Y

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 49 ( 1 ) page: 13 - 18   2022.1

     More details

    Language:Japanese  

    PubMed

  11. Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer

    Takano Yuko, Furune Satoshi, Miyai Yuki, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page: 67 - 70   2022.1

     More details

  12. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment (Oct, 10.1007/s13691-021-00515-w, 2021)

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page: 49 - 49   2022.1

     More details

  13. Vitiligo and tumor response in a patient with amelanotic melanoma undergoing nivolumab treatment

    Furune Satoshi, Kondo Chiaki, Takano Yuko, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Maeda Osamu, Ando Yuichi

    INTERNATIONAL CANCER CONFERENCE JOURNAL   Vol. 11 ( 1 ) page: 46 - 48   2022.1

     More details

  14. Bias-Dependence of Electroluminescence in AlGaN/GaN High-Electron-Mobility Transistors on SiC Substrate

    Ma Qiang, Urano Shiyo, Tanaka Atsushi, Ando Yuji, Wakejima Akio

    IEEE JOURNAL OF THE ELECTRON DEVICES SOCIETY   Vol. 10   page: 297 - 300   2022

     More details

    Language:Japanese  

    DOI: 10.1109/JEDS.2022.3163379

    Web of Science

  15. COVID-19 Pandemic and Trends in Clinical Trials: A Multi-Region and Global Perspective

    Nishiwaki Satoshi, Ando Yuichi

    FRONTIERS IN MEDICINE   Vol. 8   page: 812370   2021.12

     More details

  16. Neoadjuvant docetaxel, oxaliplatin plus S-1 for treating clinical stage III squamous cell carcinoma of the esophagus: Study protocol of an open-label phase II trial

    Kanda Mitsuro, Shimizu Dai, Miyata Kazushi, Maeda Osamu, Tanaka Chie, Inokawa Yoshikuni, Hattori Norofumi, Hayashi Masamichi, Ando Masahiko, Kuwatsuka Yachiyo, Murotani Kenta, Nakayama Goro, Koike Masahiko, Ando Yuichi, Ebata Tomoki, Kodera Yasuhiro

    CONTEMPORARY CLINICAL TRIALS COMMUNICATIONS   Vol. 24   page: 100853   2021.12

     More details

  17. A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

    Schoffski Patrick, Concin Nicole, Suarez Cristina, Subbiah Vivek, Ando Yuichi, Ruan Shiling, Wagner Joel P., Mansfield Keith, Zhu Xu, Origuchi Shizuka, DiDominick Sarah, Bialucha Carl U., Faris Jason E., Tran Ben

    ONCOLOGY RESEARCH AND TREATMENT   Vol. 44 ( 10 ) page: 547 - 556   2021.10

     More details

  18. Clinical course of liver injury induced by immune checkpoint inhibitors in patients with advanced malignancies

    Ito Takanori, Ishigami Masatoshi, Yamamoto Takafumi, Mizuno Kazuyuki, Yamamoto Kenta, Imai Norihiro, Ishizu Yoji, Honda Takashi, Kawashima Hiroki, Yasuda Satoshi, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Nishio Naoki, Maeda Osamu, Kato Masashi, Hashimoto Naozumi, Hibi Hideharu, Kodera Yasuhiro, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Shimoyama Yoshie, Fujishiro Mitsuhiro

    HEPATOLOGY INTERNATIONAL   Vol. 15 ( 5 ) page: 1278 - 1287   2021.10

     More details

  19. Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review

    Kazama Shingo, Morimoto Ryota, Kimura Yuki, Shibata Naoki, Ozaki Reina, Araki Takashi, Mizutani Takashi, Oishi Hideo, Arao Yoshihito, Kuwayama Tasuku, Hiraiwa Hiroaki, Kondo Toru, Furusawa Kenji, Shimokata Tomoya, Okumura Takahiro, Bando Yasuko K., Ando Yuichi, Murohara Toyoaki

    CARDIO-ONCOLOGY   Vol. 7 ( 1 ) page: 26   2021.7

     More details

  20. A case of recurrent gastric cancer with drug-induced immune thrombocytopenia caused by trastuzumab

    Takano Yuko, Furune Satoshi, Morita Sachi, Inoue Megumi, Shimokata Tomoya, Sugishita Mihoko, Mitsuma Ayako, Osamu Maeda, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 32   page: S354 - S354   2021.7

     More details

  21. Guidelines for clinical evaluation of anti-cancer drugs

    Minami Hironobu, Kiyota Naomi, Kimbara Shiro, Ando Yuichi, Shimokata Tomoya, Ohtsu Atsushi, Fuse Nozomu, Kuboki Yasutoshi, Shimizu Toshio, Yamamoto Noboru, Nishio Kazuto, Kawakami Yutaka, Nihira Shin-ichi, Sase Kazuhiro, Nonaka Takahiro, Takahashi Hideaki, Komori Yukiko, Kiyohara Koshin

    CANCER SCIENCE   Vol. 112 ( 7 ) page: 2563 - 2577   2021.7

     More details

  22. Phase I Assessment of Safety and Therapeutic Activity of BAY1436032 in Patients with IDH1-Mutant Solid Tumors

    Wick Antje, Baehr Oliver, Schuler Martin, Rohrberg Kristoffer, Chawla Sant P., Janku Filip, Schiff David, Heinemann Volker, Narita Yoshitaka, Lenz Heinz-Josef, Ikeda Masafumi, Ando Yuichi, Wick Wolfgang, Steinbach Joachim P., Burger Michael C., Wenger Katharina, Lassen Ulrik, Sankhala Kamalesh K., Roggia Cristiana, Genvresse Isabelle, Munhoz Catya, Rentzsch Christine, Reschke Susanne, Langer Simon, Wagner Markus, Kaulfuss Stefan, Cai Charles, Lagkadinou Eleni, Jeffers Michael, Pena Carol, Tabatabai Ghazaleh

    CLINICAL CANCER RESEARCH   Vol. 27 ( 10 ) page: 2723 - 2733   2021.5

     More details

  23. Phase I study of the antiprogrammed cell death-1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies

    Minami Hironobu, Doi Toshihiko, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Mitsuma Ayako, Shimokata Tomoya, Naito Yoichi, Matsubara Nobuaki, Tajima Takeshi, Tokushige Kota, Ishihara Kae, Cameron Scott, Ando Yuichi

    CANCER SCIENCE   Vol. 112 ( 2 ) page: 725 - 733   2021.2

     More details

  24. Randomised phase II trial of capecitabine plus oxaliplatin with continuous versus intermittent use of oxaliplatin as adjuvant chemotherapy for stage II/III colon cancer (CCOG-1302 study)

    Nakayama Goro, Takano Nao, Taniguchi Hiroya, Ishigure Kiyoshi, Yokoyama Hiroyuki, Teramoto Hitoshi, Hashimoto Ryoji, Sakai Mitsuru, Ishiyama Akiharu, Kinoshita Takashi, Hayashi Naomi, Nakamura Masanori, Hattori Norifumi, Sato Yusuke, Umeda Shinichi, Uehara Kei, Aiba Toshisada, Sonohara Fuminori, Hayashi Masamichi, Kanda Mitsuro, Kobayashi Daisuke, Tanaka Chie, Yamada Suguru, Koike Masahiko, Fujiwara Michitaka, Murotani Kenta, Ando Masahiko, Ando Yuichi, Muro Kei, Kodera Yasuhiro

    EUROPEAN JOURNAL OF CANCER   Vol. 144   page: 61 - 71   2021.2

     More details

  25. Protocol for a multi-site, cluster-randomized, phase III, comparative clinical trial of geriatric assessment of older patients with non-small-cell lung cancer: the ENSURE-GA study

    Tsubata Yukari, Shinomiya Shun, Inoue Koji, Ishikawa Nobuhisa, Saito Ryota, Nakashima Kazuhisa, Hotta Katsuyuki, Hamada Akinobu, Nagashima Fumio, Ando Yuichi, Morita Satoshi, Kobayashi Kunihiko, Isobe Takeshi

    BMC GERIATRICS   Vol. 21 ( 1 ) page: 74   2021.1

  26. PhaseIIclinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors

    Nishida Yoshihiro, Urakawa Hiroshi, Nakayama Robert, Kobayashi Eisuke, Ozaki Toshifumi, Ae Keisuke, Matsumoto Yoshihiro, Tsuchiya Hiroyuki, Goto Takahiro, Hiraga Hiroaki, Naka Norifumi, Takahashi Shunji, Ando Yuichi, Ando Masahiko, Kuwatsuka Yachiyo, Hamada Shunsuke, Ueda Takafumi, Kawai Akira

    INTERNATIONAL JOURNAL OF CANCER   Vol. 148 ( 1 ) page: 140 - 149   2021.1

     More details

  27. Chemotherapy for biliary tract cancer: real-world experience in a single institute

    Maeda Osamu, Ebata Tomoki, Shimokata Tomoya, Matsuoka Ayumu, Inada-Inoue Megumi, Morita Sachi, Takano Yuko, Urakawa Hiroshi, Miyai Yuki, Sugishita Mihoko, Mitsuma Ayako, Ando Masahiko, Mizuno Takashi, Nagino Masato, Ando Yuichi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page: 725 - 733   2020.11

     More details

  28. What is the impact of systemic chemotherapy for lateral lymph nodes in patients with locally advanced low rectal cancer?

    Ogura Atsushi, Uehara Kay, Aiba Toshisada, Hattori Norifumi, Nakayama Goro, Maeda Osamu, Ando Yuichi, Kodera Yasuhiro, Ebata Tomoki, Nagino Masato

    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE   Vol. 35 ( 11 ) page: 2073 - 2080   2020.11

     More details

  29. Solitary fibrous tumor/hemangiopericytoma treated with temozolomide plus bevacizumab: a report of four cases and literature review

    Maeda Osamu, Ohka Fumiharu, Maesawa Satoshi, Matsuoka Ayumu, Shimokata Tomoya, Mitsuma Ayako, Urakawa Hiroshi, Nakamura Shota, Shimoyamas Yoshic, Nakaguro Masato S., Wakabayashi Toshihiko, Ando Yuichi

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 82 ( 4 ) page: 631 - 644   2020.11

     More details

  30. Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial

    Nishida Yoshihiro, Hamada Shunsuke, Urakawa Hiroshi, Ikuta Kunihiro, Sakai Tomohisa, Koike Hiroshi, Ito Kan, Emoto Ryo, Ando Yuichi, Matsui Shigeyuki

    CANCER SCIENCE   Vol. 111 ( 11 ) page: 4187 - 4194   2020.11

     More details

  31. Gap between pediatric and adult approvals of molecular targeted drugs

    Nishiwaki Satoshi, Ando Yuichi

    SCIENTIFIC REPORTS   Vol. 10 ( 1 ) page: 17145   2020.10

     More details

  32. Phase I Study of LFA102 in Patients With Advanced Breast Cancer or Castration-resistant Prostate Cancer

    Minami Hironobu, Ando Yuichi, Tamura Kenji, Tajima Takeshi, Isaacs Randi

    ANTICANCER RESEARCH   Vol. 40 ( 9 ) page: 5229 - 5235   2020.9

     More details

  33. 5-FU, Irinotecan, Nab-Paclitaxel in Gastrointestinal Cancers-Letter

    Maeda Osamu, Shimokata Tomoya, Ando Yuichi

    CLINICAL CANCER RESEARCH   Vol. 26 ( 14 ) page: 3889 - 3889   2020.7

     More details

  34. Experiences and hidden needs of older patients, their families and their physicians in palliative chemotherapy decision-making: a qualitative study

    Tsuboi Rie, Sugishita Mihoko, Hirakawa Yoshihisa, Ando Yuichi

    JAPANESE JOURNAL OF CLINICAL ONCOLOGY   Vol. 50 ( 7 ) page: 779 - 786   2020.7

     More details

  35. Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study

    Urakawa Hiroshi, Ando Yuichi, Hase Tetsunari, Kikumori Toyone, Arai Eisuke, Maeda Osamu, Mitsuma Ayako, Sugishita Mihoko, Shimokata Tomoya, Ikuta Kunihiro, Ishiguro Naoki, Nishida Yoshihiro

    INTERNATIONAL JOURNAL OF CANCER   Vol. 146 ( 12 ) page: 3504 - 3515   2020.6

     More details

  36. Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies

    Mizuno Kazuyuki, Ito Takanori, Ishigami Masatoshi, Ishizu Yoji, Kuzuya Teiji, Honda Takashi, Kawashima Hiroki, Inukai Yosuke, Toyoda Hidenori, Yokota Kenji, Hase Tetsunari, Maeda Osamu, Kiyoi Hitoshi, Nagino Masato, Hibi Hideharu, Kodera Yasuhiro, Fujimoto Yasushi, Sone Michihiko, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Fujishiro Mitsuhiro

    JOURNAL OF GASTROENTEROLOGY   Vol. 55 ( 6 ) page: 653 - 661   2020.6

     More details

  37. Phase II clinical trial of pazopanib for patients with unresectable or metastatic malignant peripheral nerve sheath tumors.

    Nishida Yoshihiro, Urakawa Hiroshi, Nakayama Robert, Ozaki Toshifumi, Ae Keisuke, Matsumoto Yoshihiro, Ando Yuichi, Kuwatsuka Yachiyo, Ueda Takafumi, Kawai Akira

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 38 ( 15 )   2020.5

     More details

    Language:Japanese  

    Web of Science

  38. Significance of meflin-positive cancer-associated fibroblasts in predicting response to immune checkpoint inhibitors in non-small cell lung cancer.

    Miyai Yuki, Enomoto Atsushi, Ando Yuichi, Takahashi Masahide

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 38 ( 15 )   2020.5

     More details

    Language:Japanese  

    Web of Science

  39. Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

    Okada Norio, Iwama Shintaro, Okuji Takayuki, Kobayashi Tomoko, Yasuda Yoshinori, Wada Eri, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Hase Tetsunari, Morise Masahiro, Kanda Mitsuro, Yokota Kenji, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Nagino Masato, Kodera Yasuhiro, Fujishiro Mitsuhiro, Hibi Hideharu, Sone Michihiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    BRITISH JOURNAL OF CANCER   Vol. 122 ( 6 ) page: 771 - 777   2020.3

     More details

  40. Detection of bacteria in blood circulation in patients receiving cancer chemotherapy

    Ota Akiko, Morita Sachi, Matsuoka Ayumu, Shimokata Tomoya, Maeda Osamu, Mitsuma Ayako, Yagi Tetsuya, Asahara Takashi, Ando Yuichi

    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY   Vol. 25 ( 1 ) page: 210 - 215   2020.1

     More details

  41. Correlation Between the Metabolic Conversion of a Capecitabine Metabolite, 5 '-Deoxy-5-fluorocytidine, and Creatinine Clearance

    Inaishi Takahiro, Fujita Ken-Ichi, Matsumoto Natsumi, Shimokata Tomoya, Maeda Osamu, Kikumori Toyone, Hattori Norifumi, Nakayama Goro, Ando Yuichi

    IN VIVO   Vol. 34 ( 6 ) page: 3539 - 3544   2020

     More details

  42. Pituitary dysfunction induced by immune checkpoint inhibitors is associated with better overall survival in both malignant melanoma and non-small cell lung carcinoma: a prospective study

    Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Okuji Takayuki, Ito Masaaki, Onoue Takeshi, Goto Motomitsu, Sugiyama Mariko, Tsunekawa Taku, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Fujimoto Yasushi, Hibi Hideharu, Sone Michihiko, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    JOURNAL FOR IMMUNOTHERAPY OF CANCER   Vol. 8 ( 2 )   2020

  43. Application of the New Process for Unapproved Drug Use: Dilemma of Universal Health Care Coverage in Japan

    Nishiwaki Satoshi, Ando Yuichi

    JOURNAL OF GLOBAL ONCOLOGY   Vol. 5   page: 1 - 3   2019.11

  44. A longitudinal tracking and quantitative assessment of paclitaxel-induced peripheral neurotoxicity

    Matsuoka A., Mitsuma A., Maeda O., Tsunoda N., Kikumori T., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 30   2019.10

     More details

    Language:Japanese  

    Web of Science

  45. Selection of chemotherapy based on geriatric assessment for elderly patients with pancreatic cancer

    Maeda Osamu, Matsuoka Ayumu, Yanagawa Madoka, Muroyama Yukie, Kuzuya Masafumi, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 30   page: 131 - 131   2019.10

     More details

    Language:Japanese  

    DOI: 10.1093/annonc/mdz343.060

    Web of Science

  46. Safety, efficacy, PK and PD biomarker results of the first-in-human study of mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor BAY 1436032 in patients (pts) with mIDH1 advanced solid tumours

    Wick W., Tabatabai G., Schuler M., Rorhberg K., Chawla S. P., Janku F., Schiff D., Heinemann V., Narita Y., Ando Y., Lenz H. J., Ikeda M., Genvresse I., Rentzsch C., Reschke S., Cyris C., Cai C., Jeffers M., Pena C., Baehr O.

    ANNALS OF ONCOLOGY   Vol. 30   page: 170 - +   2019.10

     More details

    Language:Japanese  

    Web of Science

  47. Recent progress of chemotherapy and biomarkers for gastroesophageal cancer

    Maeda Osamu, Ando Yuichi

    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY   Vol. 11 ( 7 ) page: 518 - 526   2019.7

     More details

  48. Alterations in gene expression and DNA methylation profiles in gastric cancer cells obtained from ascitic fluids collected before and after chemotherapy

    Maeda Osamu, Matsuoka Ayumu, Furukawa Kazuhiro, Miyahara Ryoji, Hirooka Yoshiki, Ando Yuichi

    MOLECULAR AND CLINICAL ONCOLOGY   Vol. 11 ( 1 ) page: 91 - 98   2019.7

  49. Low-dose chemotherapy with methotrexate and vinblastine for patients with refractory desmoid tumors: A second report of relationship between efficacy and various factors.

    Nishida Yoshihiro, Sakai Tomohisa, Shimizu Koki, Urakawa Hiroshi, Arai Eisuke, Ikuta Kunihiro, Ando Yuichi, Ishiguro Naoki

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 37 ( 15 )   2019.5

     More details

    Language:Japanese  

    Web of Science

  50. Influence of tumor size and Eastern Cooperative Oncology Group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).

    Wirth Lori J., Leboulleux Sophie, Kiyota Naomi, Tahara Makoto, Muro Kei, Ahn Myung-Ju, Ando Yuichi, Taylor Matthew H., Takahashi Shunji, Kim Sung-Bae, Misir Soamnauth, Dutcus Corina E., Xie Ran, Joshi Prashant Ramesh, Hughes Brett Gordon Maxwell, Aller Javier, Krzyzanowska Monika K., Capdevila Jaume

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 37 ( 15 )   2019.5

     More details

    Language:Japanese  

    Web of Science

  51. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 Trial): study protocol for a single arm phase II study

    Takano Nao, Yamada Suguru, Hirakawa Akihiro, Yokoyama Yukihiro, Kawashima Hiroki, Maeda Osamu, Okada Tohru, Ohno Eizaburo, Yamaguchi Junpei, Ishikawa Takuya, Sonohara Fuminori, Suenaga Masaya, Takami Hideki, Hayashi Masamichi, Niwa Yukiko, Hirooka Yoshiki, Ito Yoshiyuki, Naganawa Shinji, Ando Yuichi, Nagino Masato, Goto Hidemi, Fuji Tsutomu, Kodera Yasuhiro

    NAGOYA JOURNAL OF MEDICAL SCIENCE   Vol. 81 ( 2 ) page: 233 - 239   2019.5

     More details

  52. Modified Docetaxel plus Cisplatin plus Capecitabine (DCX) for Gastric Cancer

    Maeda Osamu, Ando Yuichi, Matsuoka Ayumu, Furukawa Kazuhiro, Funasaka Kohei, Miyahara Ryoji, Hirooka Yoshiki, Goto Hidemi

    DIGESTION   Vol. 99 ( 1 ) page: 113 - 113   2019

     More details

    Language:Japanese  

    Web of Science

  53. Spiritual pain and care needs of elderly cancer patients facing palliative chemotherapy decision-making: Qualitative study.

    Tsuboi Rie, Sugishita Mihoko, Hirakawa Hirohisa, Ando Yuichi

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 34 )   2018.12

  54. Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft-tissue sarcoma

    Yonemori Kan, Kodaira Makoto, Satoh Taroh, Kudo Toshihiro, Takahashi Shunji, Nakano Kenji, Ando Yuichi, Shimokata Tomoya, Mori Joji, Inoue Koichi, Oakley Gerard J., Sakaguchi Sachi, Tamura Kenji

    CANCER SCIENCE   Vol. 109 ( 12 ) page: 3962 - 3970   2018.12

  55. Reporting harms more transparently in trials of cancer drugs

    Gyawali Bishal, Shimokata Tomoya, Honda Kazunori, Ando Yuichi

    BMJ-BRITISH MEDICAL JOURNAL   Vol. 363   page: k4383   2018.11

  56. Cabozantinib in Hepatocellular Carcinoma

    Maeda Osamu, Ando Yuichi

    NEW ENGLAND JOURNAL OF MEDICINE   Vol. 379 ( 14 ) page: 1384 - 1384   2018.10

     More details

  57. Cabozantinib in Hepatocellular Carcinoma.

    Maeda O, Ando Y

    The New England journal of medicine   Vol. 379 ( 14 ) page: 1384   2018.10

     More details

  58. A longitudinal study of a new point-of-care nerve conduction device for quantitative assessment of chemotherapy-induced peripheral neurotoxicity

    Matsuoka A., Maeda O., Mitsuma A., Uehara K., Nakayama G., Nagino M., Kodera Y., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 29   2018.10

     More details

  59. Docetaxel, cisplatin and fluorouracil as neoadjuvant chemotherapy for esophageal cancer with prophylactic pegfilgrastim

    Maeda Osamu, Koike Masahiko, Fukaya Masahide, Miyata Kazushi, Iwata Naoki, Nagino Masato, Kodera Yasuhiro, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 29   2018.10

     More details

  60. Outpatient chemotherapy for patients with unresectable or metastatic bone sarcomas

    Urakawa Hiroshi, Nishida Yoshihiro, Mitsuma Ayako, Maeda Osamu, Sugishita Mihoko, Shimokata Tomoya, Mizutani Takeshi, Arai Eisuke, Ikuta Kunihiro, Hamada Shunsuke, Ota Takehiro, Ishiguro Naoki, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 29   2018.10

     More details

  61. Phase I study of spartalizumab (PDR001), an anti-PD1 mAb, in Japanese patients with advanced malignancies

    Ando Yuichi, Doi Toshihiko, Mitsuma Ayako, Mizutani Takefumi, Toyoda Masanori, Imamura Yoshinori, Kiyota Naomi, Naito Yoichi, Matsubara Nobuaki, Ishihara Kae, Tajima Takeshi, Tokushige Kota, Cameron Scott, Minami Hironobu

    ANNALS OF ONCOLOGY   Vol. 29   2018.10

     More details

  62. Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG-1201 Study)

    Nakayama Goro, Mitsuma Ayako, Sunagawa Yuki, Ishigure Kiyoshi, Yokoyama Hiroyuki, Matsui Takanori, Nakayama Hiroshi, Nakata Kazuhiko, Ishiyama Akiharu, Asada Takahiro, Umeda Shinichi, Ezaka Kazuhiro, Hattori Norifumi, Takami Hideki, Kobayashi Daisuke, Tanaka Chie, Kanda Mitsuro, Yamada Suguru, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro

    ONCOLOGIST   Vol. 23 ( 8 ) page: 919 - 927   2018.8

  63. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer

    Yamada Suguru, Fujii Tsutomu, Yokoyama Yukihiro, Kawashima Hiroki, Maeda Osamu, Suzuki Kojiro, Okada Tohru, Ono Eizaburo, Yamaguchi Junpei, Takano Nao, Takami Hideki, Hayashi Masamichi, Niwa Yukiko, Hirooka Yoshiki, Ito Yoshiyuki, Naganawa Shinji, Ando Yuichi, Nagino Masato, Goto Hidemi, Kodera Yasuhiro

    CANCER CHEMOTHERAPY AND PHARMACOLOGY   Vol. 81 ( 5 ) page: 815 - 821   2018.5

  64. Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study

    Kobayashi Tomoko, Iwama Shintaro, Yasuda Yoshinori, Okada Norio, Tsunekawa Taku, Onoue Takeshi, Takagi Hiroshi, Hagiwara Daisuke, Ito Yoshihiro, Morishita Yoshiaki, Goto Motomitsu, Suga Hidetaka, Banno Ryoichi, Yokota Kenji, Hase Tetsunari, Morise Masahiro, Hashimoto Naozumi, Ando Masahiko, Kiyoi Hitoshi, Gotoh Momokazu, Ando Yuichi, Akiyama Masashi, Hasegawa Yoshinori, Arima Hiroshi

    JOURNAL OF THE ENDOCRINE SOCIETY   Vol. 2 ( 3 ) page: 241 - 251   2018.3

  65. Phase II trial of oral S-1 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard chemotherapies (CCOG-1105 study).

    Ezaka Kazuhiro, Nakayama Goro, Yokoyama Hiroyuki, Matsui Takanori, Umeda Shinichi, Sunagawa Yuki, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 4 )   2018.2

     More details

  66. Randomized phase II trial of CapOX plus bevacizumab versus CapIRI plus bevacizumab as first-line treatment in Japanese patients with metastatic colorectal cancer (CCOG-1201).

    Sasahara Masahiro, Nakayama Goro, Ishigure Kiyoshi, Yokoyama Hiroyuki, Uehara Keisuke, Ishiyama Akiharu, Matsui Takanori, Nakayama Hiroshi, Kobayashi Daisuke, Umeda Shinichi, Sunagawa Yuki, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 36 ( 4 )   2018.2

     More details

  67. Guidelines for treatment of renal injury during cancer chemotherapy 2016

    Horie Shigeo, Oya Mototsugu, Nangaku Masaomi, Yasuda Yoshinari, Komatsu Yasuhiro, Yanagita Motoko, Kitagawa Yuko, Kuwano Hiroyuki, Nishiyama Hiroyuki, Ishioka Chikashi, Takaishi Hiromasa, Shimodaira Hideki, Mogi Akira, Ando Yuichi, Matsumoto Koji, Kadowaki Daisuke, Muto Satoru

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   Vol. 22 ( 1 ) page: 210 - 244   2018.2

  68. Real-world experience with FOLFIRINOX and gemcitabine plus nab-paclitaxel in the treatment of pancreatic cancer in Japan

    Maeda O., Yokoyama Y., Yamaguchi J., Ota A., Matsuoka A., Morita S., Inoue M., Mizutani T., Shimokata T., Urakawa H., Mitsuma A., Nagino M., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28   page: 69 - 69   2017.11

     More details

  69. FDA Approval Summary: Sonidegib-Letter

    Gyawali Bishal, Ando Yuichi

    CLINICAL CANCER RESEARCH   Vol. 23 ( 19 ) page: 5993 - 5993   2017.10

  70. Gemcitabine plus cisplatin and S-1 for biliary tract cancer: a single institute analysis

    Maeda Osamu, Shimokata Tomoya, Mizutani Takefumi, Inoue Megumi, Matsuoka Ayumu, Ota Akiko, Mizuno Takashi, Ebata Tomoki, Nagino Masato, Ando Yuichi

    ANNALS OF ONCOLOGY   Vol. 28   page: 50 - 50   2017.10

     More details

  71. Correlation and differences in Effect sizes between Progression Free Survival (PFS) and Overall Survival (OS) among PD-1 inhibitors

    Gyawali B., Shimokata T., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28   2017.9

     More details

  72. A phase 1 study of BYL719, an a-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies

    Tomomatsu J., Iwasa S., Saka H., Takahashi S., Nakano K., Morita S., Inoue M., Nakahama H., Kogure Y., Kakizume T., Natsume K., Aoki T., Quadt C., Yamada Y., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28   2017.9

     More details

  73. Erratum: High-dose chemotherapy with autologous peripheral blood stem cell transplantation for choriocarcinoma: A case report and literature review.

    Yamamoto E, Niimi K, Fujikake K, Nishida T, Murata M, Mitsuma A, Ando Y, Kikkawa F

    Molecular and clinical oncology   Vol. 7 ( 3 ) page: 510   2017.9

     More details

  74. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902)

    Nakayama Goro, Ishigure Kiyoshi, Yokoyama Hiroyuki, Uehara Keisuke, Kojima Hiroshi, Ishiyama Akiharu, Hayashi Naomi, Takano Nao, Hattori Norifumi, Kobayashi Daisuke, Tanaka Chie, Hayashi Masamichi, Kanda Mitsuro, Yamada Suguru, Sugimoto Hiroyuki, Koike Masahiko, Fujiwara Michitaka, Fujii Tsutomu, Murotani Kenta, Ando Yuichi, Kodera Yasuhiro

    BMC CANCER   Vol. 17 ( 1 ) page: 243   2017.4

  75. Adjuvant sunitinib for high-risk-resected renal cell carcinoma: a meta-analysis of ASSURE and S-TRAC trials

    Gyawali B., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28 ( 4 ) page: 898 - 899   2017.4

  76. Assessment of left ventricular diastolic function during trastuzumab treatment in patients with HER2-positive breast cancer

    Honda Kazunori, Takeshita Kyosuke, Murotani Kenta, Mitsuma Ayako, Hayashi Hironori, Tsunoda Nobuyuki, Kikumori Toyone, Murohara Toyoaki, Ando Yuichi

    BREAST CANCER   Vol. 24 ( 2 ) page: 312 - 318   2017.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/s12282-016-0705-4

    Web of Science

    PubMed

  77. [Nephropathy in Patients Undergoing Cancer Drug Therapy - Platinum Derivatives(Cisplatin and Carboplatin)].

    Matsuoka A, Ando Y

    Gan to kagaku ryoho. Cancer & chemotherapy   Vol. 44 ( 3 ) page: 200 - 203   2017.3

     More details

  78. Modified docetaxel, cisplatin and capecitabine for stage. gastric cancer in Japanese patients: A feasibility study

    Maeda Osamu, Matsuoka Ayumu, Miyahara Ryoji, Funasaka Kohei, Hirooka Yoshiki, Fukaya Masahide, Nagino Masato, Kodera Yasuhiro, Goto Hidemi, Ando Yuichi

    WORLD JOURNAL OF GASTROENTEROLOGY   Vol. 23 ( 6 ) page: 1090 - 1097   2017.2

  79. Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials

    Gyawali B., Shimokata T., Ando M., Honda K., Ando Y.

    ANNALS OF ONCOLOGY   Vol. 28 ( 2 ) page: 246 - 253   2017.2

  80. Unconvincing Benefit of Combination TherapyWith Gefitinib and Pemetrexed in Advanced Non-Small-Cell Lung Cancer

    Ota Akiko, Gyawali Bishal, Matsuoka Ayumu, Ando Yuichi

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 35 ( 6 ) page: 691 - +   2017.2

  81. Carboplatin dosing for adult Japanese patients Invited Reviewed

    Yuichi Ando, Tomoya Shimokata, Yoshinari Yasuda, and Yoshinori Hasegawa.

    Nagoya J Med Sci   Vol. 76 ( 1 ) page: 1-9   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  82. A Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors. Reviewed

    Yuichi Ando, Megumi Inada-inoue, Ayako Mitsuma, Takayuki Yoshino, Atsushi Ohtsu, Naoko Suenaga, Masahiko Sato, Tomoyuki Kakizume, Matthew Robson, Cornelia Quadt, Toshihiko Doi.

    Cancer Sci   Vol. 105 ( 3 ) page: 347-53   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  83. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Reviewed

    Cancer Sci   Vol. 101   page: 2601-5   2010

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

  84. UGT1A1*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Invited Reviewed

    Yuichi Ando, et al.

    Curr Opin Mol Ther   Vol. 9   page: 258-262   2007

     More details

    Authorship:Lead author   Language:English  

  85. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Reviewed

    Yuichi Ando, et al.

    Cancer Res   Vol. 60   page: 6921-6926   2000

     More details

    Authorship:Lead author   Language:English   Publishing type:Research paper (scientific journal)  

▼display all

Books 3

  1. 高齢者のがん薬物療法ガイドライン

    統括委員長 安藤雄一

    編集:日本臨床腫瘍学会・日本癌治療学会  2019.7 

     More details

    Language:Japanese Book type:Scholarly book

  2. 治療学 内科学総論 内科学書

    安藤雄一( Role: Contributor)

    中山書店  2019 

     More details

    Language:Japanese

  3. 薬物動態・薬力学.新臨床腫瘍学 がん薬物療法専門医のために

    安藤雄一( Role: Contributor)

    南江堂  2018 

     More details

    Language:Japanese

KAKENHI (Grants-in-Aid for Scientific Research) 14

  1. 抗がん薬による下痢・腸炎の病態解明と新治療法の開発

    2017.4 - 2020.3

    科学研究費補助金  基盤研究(C)

  2. がん薬物療法におけるサルコペニアの臨床的意義

    2014.4 - 2017.3

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  3. Mechanism of predicting the effects of immune checkpoint inhibitors based on the diversity of cancer-associated fibroblasts

    Grant number:20H03528  2020.4 - 2023.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

      More details

    Authorship:Principal investigator 

    Grant amount:\17290000 ( Direct Cost: \13300000 、 Indirect Cost:\3990000 )

  4. Exploratory analysis of DNA methylation as a novel biomarker in gastrointestinal cancer chemotherapy

    Grant number:20K08328  2020.4 - 2023.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  5. がん薬物療法における抗がん薬曝露に対する科学的エビデンスの創出

    Grant number:19K07083  2019.4 - 2023.3

    科学研究費助成事業  基盤研究(C)

    満間 綾子, 安藤 雄一, 下方 智也

      More details

    Authorship:Coinvestigator(s) 

    新規抗がん薬の開発により、外来化学療法で取り扱う抗がん薬レジメンは増加する一方である。外来化学療法室の利用患者は年々増加し、多様なニーズに応えるがん薬物療法に習熟した医療者の関わりが重要となっている。がん薬物療法を専門とする医療者の育成、拡充にあたっては、専門的な教育・訓練とともに抗がん薬を扱う現場における医療者の安全、職場環境の整備も提唱されている。曝露防止のための機器開発が進む中で過去の報告は現状と乖離しており、医療者がコストと時間をかけてどこまで曝露対策を行うかの科学的実証は未確立である。本研究では、抗がん薬曝露の実態を経年的・経時的に調査し現状に即したエビデンスを創出する。
    本研究では、がん薬物療法における抗がん薬曝露の実態を調査し、繰り返しモニタリングを行うことで、国内での閾値の設定や予防の根拠となるエビデンスを創出することを目的としている。当院外来化学療法室では、院内すべての点滴抗がん薬の外来投与を専任の医療者が担当している。年間10000件以上の実施にあたり、職業性曝露のモニタリングとして環境モニタリングと生物学的モニタリングの経年的実施を行う。
    <環境モニタリング>
    当院外来化学療法室での環境モニタリングを行うにあたり、モニタリングの手法、場所を絞り込んだ後に、抗がん薬曝露予防を目的とした機器導入、マニュアルの改訂・整備の現状を把握できている。閉鎖式薬物移送システム(closed system drug transfer device: CSTD) は、当院において抗がん薬のミキシングすべてには使用していない。揮発性抗がん薬にのみCSTDを使用している。これまでのモニタリング結果では既報に比べて汚染の度合いを示す測定値は低く、現状での手法により経時的にモニタリングを進めている。
    <生物学的モニタリング>
    外来化学療法室で実施する膀胱内注入後の抗がん薬曝露について、同意を得た患者および医療者の排尿より生物学的モニタリングを行う。ドキソルビシンの投与が予定されており、投与量、排尿回数など臨床薬理学的解析を加えて経時的変化を観察する予定であったが、治療対象者が乏しい状況が続いている。がん関連学会での情報収集を継続した。侵襲の程度が少ない新たな手法(唾液検体からの検出)では検体量の採取に時間がかかることが判明した。
    環境モニタリングは順調に推移している。昨年同様、生物学的モニタリングは対象患者が乏しい状況があった。新規薬剤の導入やCOVID-19により高齢患者など地元での治療ニーズが高い影響を考える。
    生物学的モニタリングの対象となる泌尿器疾患の患者が減少している。新規薬剤の導入やCOVID-19による影響が考えられ、今後の増加は難しい状況である。研究代表者および研究分担者との討議を定期的に行っており、引き続き現状での研究の推進に努める。

  6. Factors involved in the efficacy and safety of biopharmaceuticals

    Grant number:19K07224  2019.4 - 2022.3

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (C)

      More details

    Authorship:Coinvestigator(s) 

  7. Mechanism of diarrhea/enteritis caused by anticancer drugs and development of new treatment

    Grant number:17K08950  2017.4 - 2020.3

    Ando Yuichi

      More details

    Authorship:Principal investigator 

    Grant amount:\3510000 ( Direct Cost: \2700000 、 Indirect Cost:\810000 )

    By focusing on bacterial-translocation, phenomenon in which human intestinal bacteria migrate into circulating blood in human body via intestinal wall, using highly-sensitive detection assay for viable bacteria, I investigated whether bacteria in the blood would be associated with the occurrence of adverse effects of cancer chemotherapy. The results revealed that patients with cancer were always prone to bacterial-translocations regardless of the administration of anticancer drugs, suggesting that bacterial-translocation would be the cause of febrile neutropenia, infection, and diarrhea/enteritis, which are caused by cancer chemotherapy.

  8. Screening and prevention of vascular events for cancer patients, and investigation of the mechanisms.

    Grant number:16K08906  2016.4 - 2020.3

    Mitsuma Ayako

      More details

    Authorship:Coinvestigator(s) 

    Some newly developed cancer chemotherapy drugs cause hemorrhage or thrombosis as adverse event through inhibition of angiogenesis. Prolonged survival and aging of cancer patients lead to increase of patients using anticoagulats to prevent cardiovascular disease. In this study we evaluated risk of cancer associated thrombosis receiving outpatient treatment, including drug interactions. We compared our data with predictive model proposed in foreign studies. We found no difference in outcome of treatment with specific anticoagulants. Effects of cancer chemotherapy and condition of patients influenced clinical course of thrombosis.

  9. Study of the infusion reaction by rituximab

    Grant number:16K08374  2016.4 - 2019.3

    Nakamura Katsunori

      More details

    Authorship:Coinvestigator(s) 

    Infusion reaction is a side effect that occurs immediately after antibody drug administration, and its prediction is becoming very important. In this study, we identified infusion reaction risk factors by analyzing genetic polymorphisms in patients who developed adverse effects immediately after rituximab administration. [Significance] By identifying risk factors such as the effects of FcRn genetic polymorphism, it is expected that the optimal use of rituximab can be considered taking into consideration individual differences in their genetic polymorphism. [Importance] It is expected that this study may be generalized to antibody drugs and could be applied to "preclinical tests" performed prior to clinical trials where antibody drugs are first administered to humans.

  10. Elucidation of sarcopenia mechanism in the cancer cachexia

    Grant number:15K08906  2015.4 - 2019.3

    Shimokata Tomoya

      More details

    Authorship:Coinvestigator(s) 

    We evaluated the body composition, muscle mass and adipose tissue, in patients who received cancer pharmacotherapy to test a hypothesis that the adipose tissue plays an important role in the process to cancer cachexia. We analyzed the change of the body composition in patients who received monotherapy of the mTOR inhibitor more than six months retrospectively. The muscle mass significantly decreased, but there were no significant changes in the adipose tissue quantity. Also, we performed a cohort study to evaluate a body composition change and a metabolic rate as subjects in the patients prospectively. We accumulate 28 cases and final analysis is in progress.

  11. Establishment of bone metastasis treatment by regulating hyaluronan network and osteoclast

    Grant number:26462261  2014.4 - 2018.3

    Urakawa Hiroshi

      More details

    Authorship:Coinvestigator(s) 

    Bone metastases impair the quality of patients with malignancies. We focused on the co-effect of regulation of hyaluronan (HA) and bone modifying agents. We investigated the effects of 4-methylumbelliferone (MU) and/or bone modifying agents on HA expression in breast and lung cancer cell lines in addition to their tumorigenicity in vitro and in vivo. MU or zoledronic acid treatment individually suppressed proliferation, migration and invasion of breast and lung cancer cell lines, and combination treatment of MU and zoledronic acid showed synergistic effects. Combination therapy showed additive inhibitory effects on metastatic bone lesions in vivo, which paralleled the inhibition of HA accumulation by MU, and inhibition of osteoclastogenesis. These data suggest that inhibition of HA synthesis is a promising novel therapeutic candidate for bone metastasis in addition to bone modifying agents.

  12. Clinical significance of sarcopenia in cancer chemotherapy

    Grant number:26460626  2014.4 - 2018.3

    Ando Yuichi

      More details

    Authorship:Principal investigator 

    Grant amount:\3510000 ( Direct Cost: \2700000 、 Indirect Cost:\810000 )

    The aim of this study is investigated sarcopenia in cancer patients who underwent cancer chemotherapy in order to test the hypothesis that those patients with sarcopenia are more likely to experience severe toxicity and then poorly tolerate the treatment. First, we retrospectively analyzed the change of skeletal muscle mass in patients treated with an mTOR inhibitor and reported that the muscle mass was significantly reduced by treatment. Subsequently, an observational study was conducted to prospectively evaluate sarcopenia up to for 6 months in cancer patients who received a kinase inhibitor containing mTOR inhibitor. Of the 28 patients enrolled, 17 and 7 patients completed the 6-month and 3-month follow-ups, respectively. Final analysis of the results is in progress.

  13. がん薬物療法における血管新生阻害薬の薬物効果予測因子としての眼底所見の探索的研究

    2011.4 - 2013.3

    科学研究費補助金  基盤研究(C)

      More details

    Authorship:Principal investigator 

  14. がん薬物療法における薬剤誘発性QT延長の遺伝的要因を含めた患者要因       

    2008.4 - 2011.3

    科学研究費補助金  基盤研究(C)

    安藤 雄一

      More details

    Authorship:Principal investigator 

▼display all